Media stories about Catalent (NYSE:CTLT) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalent earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.8713847422347 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several brokerages have recently issued reports on CTLT. BidaskClub downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Jaffray Companies increased their price objective on Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, November 7th. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $48.00 price objective for the company in a report on Monday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Catalent in a report on Monday, October 23rd. Finally, ValuEngine downgraded Catalent from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $42.11.

Shares of Catalent (NYSE:CTLT) opened at $37.27 on Wednesday. The firm has a market capitalization of $5,048.66, a price-to-earnings ratio of 26.57, a P/E/G ratio of 2.44 and a beta of 1.49. Catalent has a 1-year low of $22.94 and a 1-year high of $43.39. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $490.75 million. During the same period last year, the business posted $0.16 EPS. The business’s revenue was up 23.0% compared to the same quarter last year. equities analysts anticipate that Catalent will post 1.46 EPS for the current fiscal year.

In other Catalent news, SVP Christine Dolan sold 1,594 shares of the stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Catalent (CTLT) Share Price” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with's FREE daily email newsletter.